+44 (0) 20 7549 9987 | USA callers: +1 212 220 8419

Contact Us Now

“Global Dermatological Drugs market to grow to $39bn by 2025” says Visiongain

01 November 2019
Pharma

Visiongain has launched a new pharma report Dermatological Drugs Market Report : Psoriasis, Skin Infection, Acne, Dermatitis, Others.

The dermatological drugs market is a specialist segment of the pharmaceutical market which over the last several years has been growing at a faster rate than the overall market. This has been due partly to the high growth potential of biological treatments for psoriasis. The development of new antibacterial drugs to address the problems of population ageing and drug-resistant strains of bacteria will also contribute to the overall market growth. In other segments, high generic penetration and intense competition limit profitability.

The lead analyst of the report commented "The prevention and treatment of dermatological conditions is becoming a priority for many healthcare authorities worldwide. The increasing incidence of skin and skin structure infections (SSSI) acquired in hospitals and the community is being exacerbated by resistance to existing antibacterial therapies.

Moreover, the ageing immunocompromised population will drive the increasing prevalence of skin and skin structure infections. Throughout the forecast period, we expect global demand for dermatological drugs to increase significantly. This trend will be driven by the expansion in emerging markets, where expansion in healthcare provision will increase demand. Economic growth and the expansion of the middle class in these emerging markets will further drive the demand for dermatological treatments."

Leading companies featured in the report include AbbVie, Allergan, Amgen, Bausch Health, Bayer AG, Bristol-Myers Squibb, Celgene Corporation, Eli Lilly, Galderma (Nestle Skin Health S.A.), GlaxoSmithKline (GSK) and other companies.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongaing.com or call her on +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Cell Therapy Technologies Market Report 2024-2034

The cell therapy technologies market is estimated at US$7,041.3 million in 2024 and is projected to grow at a CAGR of 10.7% during the forecast period 2024-2034.

18 April 2024

Read

Visiongain Publishes Automation in Biopharma Industry Market Report 2024-2034

The global Automation in Biopharma Industry market is estimated at US$1,954.3 million in 2024 and is projected to grow at a CAGR of 7% during the forecast period 2024-2034.

17 April 2024

Read

Visiongain Publishes Anti-obesity Drugs Market Report 2024-2034

The global Anti-obesity Drugs market is estimated at US$11,540.2 million in 2024 and is expected to register a CAGR of 21.2% from 2024 to 2034.

12 April 2024

Read

Visiongain Publishes Inflammatory Bowel Diseases (IBD) Drugs Market Report 2024-2034

The global Inflammatory Bowel Diseases (IBD) Drugs market was valued at US$27.53 billion in 2023 and is projected to grow at a CAGR of 6.2% during the forecast period 2024-2034.

11 April 2024

Read